Baird raised the firm’s price target on Nuvalent (NUVL) to $112 from $105 and keeps an Outperform rating on the shares. The firm updated its model following the release of pivotal data in Pretreated ROS1+NSCLC which confirmed its differentiated profile.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent’s Zidesamtinib: A Promising Blockbuster in the ROS1 Inhibitor Landscape
- Nuvalent price target raised to $140 from $125 at Leerink
- Nuvalent price target raised to $130 from $110 at H.C. Wainwright
- Nuvalent’s Zidesamib: Promising Best-in-Class ROS1 TKI with Strong Efficacy and Safety Profile
- Nuvalent Announces Positive Data for Zidesamtinib Trial